Substance · official US FDA label
Calcipotriol (calcipotriene)
9 medicines listed on Vimpia contain it, alone or combined. Below, the official US FDA label for calcipotriene, unchanged.
Want to buy it?
Trouver shows the pharmacies near you that have it right now, and their prices. The reservation pages are in French.
This is a US label.
The official US FDA label for calcipotriene, effective July 14, 2026, describes products sold in the United States. The medicine sold in DR Congo may differ in strength, form or approved uses: ask a pharmacist or a doctor.
Official US FDA label for calcipotriene
Data provided by the U.S. Food and Drug Administration (openFDA), unchanged. The full label on DailyMed.
Uses
INDICATIONS AND USAGE Calcipotriene ointment, 0.005%, is indicated for the treatment of plaque psoriasis in adults. The safety and effectiveness of topical calcipotriene in dermatoses other than psoriasis have not been established.
Dosage
US dosage, for products sold in the United States. For a medicine bought in DR Congo, follow its box, its leaflet or your pharmacist.
DOSAGE AND ADMINISTRATION Apply a thin layer of calcipotriene ointment once or twice daily and rub in gently and completely.
Side effects
ADVERSE REACTIONS In controlled clinical trials, the most frequent adverse reactions reported for calcipotriene were burning, itching and skin irritation, which occurred in approximately 10-15% of patients. Erythema, dry skin, peeling, rash, dermatitis, worsening of psoriasis including development of facial/scalp psoriasis were reported in 1 to 10% of patients. Other experiences reported in less than 1% of patients included skin atrophy, hyperpigmentation, hypercalcemia, and folliculitis. Once daily dosing has not been shown to be superior in safety to twice daily dosing.
Medicines that contain it
Names as they are sold. A medicine without an English page links to its French page.
- DAIVONEX 50 microgrammes/gramme, crème
- DAIVONEX 50 microgrammes/gramme, pommade
- CALCIPOTRIOL/BETAMETHASONE SANDOZ 50 microgrammes/0,5 mg/g, pommade (in French)
Combined with other substances
- CLOSALIS 50 microgrammes/0,5 mg/g, gel (in French)
Combined with other substances
- CLOSALIS 50 microgrammes/0,5 mg/g, pommade (in French)
Combined with other substances
- DAIVOBET 50 microgrammes/0,5 mg/g, gel (in French)
Combined with other substances
- DAIVOBET 50 microgrammes/0,5 mg/g, pommade (in French)
Combined with other substances
- ENSTILAR 50 microgrammes/0,5 mg/g, mousse cutanée (in French)
Combined with other substances
- XAMIOL 50 microgrammes/0,5 mg/g, gel (in French)
Combined with other substances
Sources
- ●Labels: U.S. Food and Drug Administration, openFDA (public domain). Data provided by the U.S. Food and Drug Administration (openFDA), unchanged. DailyMed.
- ●English names of substances: RxNorm, U.S. National Library of Medicine.
- ●Marketing authorizations: register of the ACOREP, DR Congo.
- ●Essential medicines: national list of essential medicines of DR Congo (LNME).
- ●Composition: public medicines database of France (BDPM), ANSM, open licence.
Public information, for reference only: it does not replace the advice of a pharmacist or a doctor. Vimpia writes nothing about how to use a medicine and translates nothing: the label is the US FDA's, unchanged; names, composition and authorizations come from the official sources above.